세계의 위암 시장에 대해 조사했으며, 시장의 개요와 1차 치료에서 Herceptin 및 trastuzumab 바이오시밀러의 진화한 역할부터 2차 치료에서 Enhertu의 유망한 가능성까지 위암 치료의 최신 진보를 자세히 살펴봅니다. 제일선에서 활약하는 KOL이 현재 치료와 새로운 옵션을 철저하게 분석하고 주요 과제와 향후 가능성을 강조하고 있습니다.
목차
개요
현재 및 향후 치료 알고리즘
조사 목적
출시 치료법
- 화학요법 레지멘, 현재 치료 동향, 과제, 미충족 요구
- Herceptin(trastuzumab; Roche)
- Enhertu(trastuzumab deruxtecan; AstraZeneca/Daiichi Sankyo)
- Cyramza(ramucirumab; Lilly)
- Keytruda(pembrolizumab; Merck & Co.)
- Opdivo(nivolumab; BMS/Ono)
후기 파이프라인 프로그램
- 면역치료
- Durvalumab(Imfinzi; AstraZeneca)
- Avelumab(Bavencio; Merck Group/Pfizer)
- Atezolizumab(Tecentriq; Roche)
- 표적 생물학적 요법
- Zolbetuximab(IMAB362/claudiximab; Astellas/Ganymed)
- Margetuximab/retifanlimab/tebotelimab(MacroGenics/Incyte)
- Bemarituzumab(Five Prime Therapeutics/Amgen)
- Zanidatamab(ZW25; Zymeworks)
- Evorpacept(ALX Oncology)
- Catumaxomab(Removab; LintonPharm)
- ARX788(Ambrx/Zhejiang Medicine)
- 표적 경구 요법
- Stivarga(regorafenib; Bayer)
- 차세대 치료법
- Sirexatamab(DKN-01; Leap Therapeutics/BeiGene)
향후 치료 동향
부록
뉴스
KSA
From the evolving role of Herceptin and trastuzumab biosimilars in first-line therapy to the promising potential of Enhertu in second-line treatment, this report delves into the latest advancements in gastric cancer therapies. Leading KOLs provide a thorough analysis of current treatments and emerging options, highlighting key challenges and future opportunities. Discover how these insights are set to transform the gastric cancer treatment landscape.
Table of Contents
Executive summary
Current and future treatment algorithm
Research objectives
Marketed treatments
- Chemotherapy regimens, current treatment trends, challenges and unmet needs
- Herceptin (trastuzumab; Roche)
- Enhertu (trastuzumab deruxtecan; AstraZeneca/Daiichi Sankyo)
- Cyramza (ramucirumab; Lilly)
- Keytruda (pembrolizumab; Merck & Co.)
- Opdivo (nivolumab; BMS/Ono)
Late-stage pipeline programmes (120)
- Immunotherapies
- Durvalumab (Imfinzi; AstraZeneca)
- Avelumab (Bavencio; Merck Group/Pfizer)
- Atezolizumab (Tecentriq; Roche)
- Targeted biologic therapies
- Zolbetuximab (IMAB362/claudiximab; Astellas/Ganymed)
- Margetuximab/retifanlimab/tebotelimab (MacroGenics/Incyte)
- Bemarituzumab (Five Prime Therapeutics/Amgen)
- Zanidatamab (ZW25; Zymeworks)
- Evorpacept (ALX Oncology)
- Catumaxomab (Removab; LintonPharm)
- ARX788 (Ambrx/Zhejiang Medicine)
- Targeted oral therapies
- Stivarga (regorafenib; Bayer)
- Next-generation therapies
- Sirexatamab (DKN-01; Leap Therapeutics/BeiGene)
Future treatment trends
- Cell therapies and gastric cancer vaccines
- Other promising technologies in the pipeline for gastric cancer
Appendix
- KOL details
- KOLs from the USA
- KOLs from Europe
News
